Taghreed Altaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taghreed Altaei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ali Odeh
Pharmacy faculty, Al-Isra University, Amman, Jordan
1 shared publication - Ali Omar Yassen
Department of Clinical Pharmacy, Faculty of Pharmacy, Tishk International University, Erbil, Iraq
1 shared publication - Aysar Amer Hameed
Department of Pharmacology, Isra University, Amman, Jordan
1 shared publication - Diyar Majid Jalil
Faculty of Pharmacy, Isra University, Amman/ Jordan
1 shared publication Ishaq Saad Al-Khalaf
Faculty of Pharmacy, Isra University, Amman/ Jordan
1 shared publicationRaad Alani
Faculty of Pharmacy, Isra University, Amman/ Jordan
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- Vol. 63 (3) , 597-606
Efficacy of silymarin on calprotectin and S100A12/EN-RAGE in chemotherapy-induced oral mucositis
Oral mucositis (OM) is an oral complication of chemotherapy with agents such as 5-fluorouracil (5-FU). Silymarin (SM) has been utilized therapeutically as a cytoprotective medication. The aim of the study was to evaluate the efficacy of SM as a mucoprotective agent in the treatment of chemotherapy-induced oral mucositis (CIOM) induced by 5-FU, and to assess calprotectin (CP) and S100A12/EN-RAGE levels as novel biomarkers for the evaluation of mucositis. Fifty Wistar albino rats of both sexes were divided randomly into 5 groups. Three groups were treated with different doses of SM (2 mg/kg, 4 mg/kg, 6 mg/kg) for 10 days. Subsequently, the animals from groups I-III received intraperitoneal injections of 5-FU (60 mg/kg) on days 11-14. The 4th group was treated with dimethyl sulfoxide (DMSO) as a control for 10 days, followed by 2 doses of 5-FU, and the 5th group served as a second control and received 5-FU only. The buccal mucosa of the animals was gently injured with a 0.8-mm orthodontic wire (2×6 strokes) under anesthesia. The efficacy of SM treatment on CP and S100A12/EN-RAGE levels in CIOM was evaluated. Macroscopic and histopathological findings were analyzed, and the correlation coefficients between the studied parameters were calculated. The study demonstrated a significant protective effect of SM in chemotherapy-induced buccal mucositis in a dose-dependent manner. Mucositis ulceration was not observed, in contrast to severe OM lesions noted in the control groups. Analysis using a 95% confidence interval (CI) showed highly significant differences between the groups regarding the levels of CP and S100A12/EN-RAGE, as well as very strong correlations with OM ulcers. Based on the macroscopic and histopathological appearance, the study confirmed the dose-dependent protective efficacy of SM treatment in CIOM. In addition, the findings suggest a novel mucoprotective mechanism of SM mediated through its effects on CP and S100A12/EN-RAGE levels. A very strong positive correlation was found between plasma CP and S100A12/EN-RAGE levels and the presence of OM ulcers, suggesting that these biomarkers may be useful in the clinical assessment of CIOM.
- 30 June 2026
- Published by Wroclaw Medical University in Dental and Medical Problems
- Vol. 63 (3) , 597-606
Open AccessEfficacy of silymarin on calprotectin and S100A12/EN-RAGE in chemotherapy-induced oral mucositis
Oral mucositis (OM) is an oral complication of chemotherapy with agents such as 5-fluorouracil (5-FU). Silymarin (SM) has been utilized therapeutically as a cytoprotective medication. The aim of the study was to evaluate the efficacy of SM as a mucoprotective agent in the treatment of chemotherapy-induced oral mucositis (CIOM) induced by 5-FU, and to assess calprotectin (CP) and S100A12/EN-RAGE levels as novel biomarkers for the evaluation of mucositis. Fifty Wistar albino rats of both sexes were divided randomly into 5 groups. Three groups were treated with different doses of SM (2 mg/kg, 4 mg/kg, 6 mg/kg) for 10 days. Subsequently, the animals from groups I-III received intraperitoneal injections of 5-FU (60 mg/kg) on days 11-14. The 4th group was treated with dimethyl sulfoxide (DMSO) as a control for 10 days, followed by 2 doses of 5-FU, and the 5th group served as a second control and received 5-FU only. The buccal mucosa of the animals was gently injured with a 0.8-mm orthodontic wire (2×6 strokes) under anesthesia. The efficacy of SM treatment on CP and S100A12/EN-RAGE levels in CIOM was evaluated. Macroscopic and histopathological findings were analyzed, and the correlation coefficients between the studied parameters were calculated. The study demonstrated a significant protective effect of SM in chemotherapy-induced buccal mucositis in a dose-dependent manner. Mucositis ulceration was not observed, in contrast to severe OM lesions noted in the control groups. Analysis using a 95% confidence interval (CI) showed highly significant differences between the groups regarding the levels of CP and S100A12/EN-RAGE, as well as very strong correlations with OM ulcers. Based on the macroscopic and histopathological appearance, the study confirmed the dose-dependent protective efficacy of SM treatment in CIOM. In addition, the findings suggest a novel mucoprotective mechanism of SM mediated through its effects on CP and S100A12/EN-RAGE levels. A very strong positive correlation was found between plasma CP and S100A12/EN-RAGE levels and the presence of OM ulcers, suggesting that these biomarkers may be useful in the clinical assessment of CIOM.
- Open Access
- 12 August 2025
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (3) , 133-138
Monitoring of patients with concomitant diseases post coronavirus infection
This survey study presents data on the prevalence of, and the risk factors associated with post-COVID-19 complications for surviving patients with concomitant diseases during and after months of infection by coronavirus. A prospective, questionnaire-based study was conducted from May 2021 to June 2022. Patients who recovered from COVID-19 in 62 countries completed the online survey or did so during visits to hospitals and health centers. Individuals who recovered from COVID-19 were asked about their symptoms, adverse effects and adverse drug reactions. They were also asked if their concomitant diseases (diabetes, cardiovascular illness, asthma and GIT diseases) were affected after infection and if they had an uncontrolled treatment regimen. The severity of COVID was studied and the correlation coefficient to uncontrolled concomitant diseases was analyzed. Overall, 844 patients (44% female, 56% male) were assessed, and the highest percentage were suffering from long-term cough, dyspnea, constipation and uncontrolled concomitant diseases. A high significantly positive correlation between the severity of COVID infection and uncontrolled concomitant diseases was recorded. Many patients with mild to severe disease presentation reported persistent symptoms months later. Long-term complications to the lungs, heart, vascular system, kidneys, as well as metabolic disruption appear as uncontrolled treatment regimens for surviving COVID-19 patients.
- 12 August 2025
- Published by Medical University of Lublin in Current Issues in Pharmacy and Medical Sciences
- Vol. 38 (3) , 133-138
Open AccessMonitoring of patients with concomitant diseases post coronavirus infection
This survey study presents data on the prevalence of, and the risk factors associated with post-COVID-19 complications for surviving patients with concomitant diseases during and after months of infection by coronavirus. A prospective, questionnaire-based study was conducted from May 2021 to June 2022. Patients who recovered from COVID-19 in 62 countries completed the online survey or did so during visits to hospitals and health centers. Individuals who recovered from COVID-19 were asked about their symptoms, adverse effects and adverse drug reactions. They were also asked if their concomitant diseases (diabetes, cardiovascular illness, asthma and GIT diseases) were affected after infection and if they had an uncontrolled treatment regimen. The severity of COVID was studied and the correlation coefficient to uncontrolled concomitant diseases was analyzed. Overall, 844 patients (44% female, 56% male) were assessed, and the highest percentage were suffering from long-term cough, dyspnea, constipation and uncontrolled concomitant diseases. A high significantly positive correlation between the severity of COVID infection and uncontrolled concomitant diseases was recorded. Many patients with mild to severe disease presentation reported persistent symptoms months later. Long-term complications to the lungs, heart, vascular system, kidneys, as well as metabolic disruption appear as uncontrolled treatment regimens for surviving COVID-19 patients.
- Open Access
- 20 March 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (1) , 565-578
Efficacy and Bioavailability of silymarin on Plasma S100B Level in Cardiotoxicity-induced Rats
Cardiotoxicity is a cause of death by drug overdose. Silymarin, a cytoprotective agent used in this research to protect against induced-cardiotoxic effects in Albino Wister rats; exhibited signs of heart damage, such as elevated levels of S100B, troponin I, and CK-MB. Seventy albino Wister rats of both genders were divided randomly with each group having 10 rats. Silymarin-treated, cardiotoxic-induced, and control groups were treated for ten days. The bioavailability of silymarin was assessed, and evaluation of the efficacy of silymarin on the biomarker S100B and cardiac biomarkers (Troponin I, and CK-MB), also the histopathological assessments of the heart, liver, and kidney, in addition to the coefficient correlation of the studied biomarkers were analyzed. Research’s outcome indicated that the sets subjected to silymarin presented substantial differences in rat weight and food consumption, compared to a decrease in cardiotoxic clusters. S100B plasma level was increased in cardiotoxic groups, reduced in those subjected to silymarin, and eliminated by pretreatment with silymarin. Troponin I & CK-MB expressively elevated significantly in cardiotoxic prompted rats, which declined with silymarin treatment and were prohibited in pretreatment by silymarin. The shielding characteristic of silymarin detected in end organs, like the liver, kidneys, and hearts when exposed to the cardiotoxic agent clozapine was extremely significant. The consequences of the histopathological examination of this study illustrated silymarin’s cardioprotective effects. A significant positive coefficient correlation of S100B with troponin I & CK-MB was recorded. In conclusion, silymarin reduces and prevents to a larger extent the cardiotoxicity brought about by clozapine and averts heart injury. The cardioprotective efficacy of silymarin is explained by its new mechanism of action as decreasing S100B, troponin I & CK-MB levels with a strong significant correlation to each other. The cardioprotective efficacy of silymarin gives promise for monitoring the cardiotoxicity adverse drug reaction induced by drugs.
- 20 March 2024
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 17 (1) , 565-578
Open AccessEfficacy and Bioavailability of silymarin on Plasma S100B Level in Cardiotoxicity-induced Rats
Cardiotoxicity is a cause of death by drug overdose. Silymarin, a cytoprotective agent used in this research to protect against induced-cardiotoxic effects in Albino Wister rats; exhibited signs of heart damage, such as elevated levels of S100B, troponin I, and CK-MB. Seventy albino Wister rats of both genders were divided randomly with each group having 10 rats. Silymarin-treated, cardiotoxic-induced, and control groups were treated for ten days. The bioavailability of silymarin was assessed, and evaluation of the efficacy of silymarin on the biomarker S100B and cardiac biomarkers (Troponin I, and CK-MB), also the histopathological assessments of the heart, liver, and kidney, in addition to the coefficient correlation of the studied biomarkers were analyzed. Research’s outcome indicated that the sets subjected to silymarin presented substantial differences in rat weight and food consumption, compared to a decrease in cardiotoxic clusters. S100B plasma level was increased in cardiotoxic groups, reduced in those subjected to silymarin, and eliminated by pretreatment with silymarin. Troponin I & CK-MB expressively elevated significantly in cardiotoxic prompted rats, which declined with silymarin treatment and were prohibited in pretreatment by silymarin. The shielding characteristic of silymarin detected in end organs, like the liver, kidneys, and hearts when exposed to the cardiotoxic agent clozapine was extremely significant. The consequences of the histopathological examination of this study illustrated silymarin’s cardioprotective effects. A significant positive coefficient correlation of S100B with troponin I & CK-MB was recorded. In conclusion, silymarin reduces and prevents to a larger extent the cardiotoxicity brought about by clozapine and averts heart injury. The cardioprotective efficacy of silymarin is explained by its new mechanism of action as decreasing S100B, troponin I & CK-MB levels with a strong significant correlation to each other. The cardioprotective efficacy of silymarin gives promise for monitoring the cardiotoxicity adverse drug reaction induced by drugs.
- Open Access
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2425-2438
Impact of Angiotensin Receptor Blockers on Angiotensin III and Leptin in Rabbits
Angiotensin III (Ang III) properties include chemotaxis, creation development factors, and chemokines, which are also involved in renal and cardiovascular functions. Angiotensin receptor blockers (ARBs) are commonly used to treat cardiovascular illnesses. One factor that contributes to controlling blood pressure and resting metabolic rate is the protein Leptin (LEP). This study aimed to analyze ARB's (Losartan, Telmisartan, or Candesartan) effects on the levels of Ang III and LEP in rabbits. The characterization of the relationship between the two factors will be studied. The study was conducted on forty Oryctolagus cuniculus male rabbits. They were divided into four groups, randomly. Treated daily for ten days with intraperitoneal Losartan 0.7 mg/kg/day [G I], Telmisartan 0.6 mg/kg/day [G II], Candesartan 0.1 mg/kg/day [G III], and Control [G IV]. Pre- and post-treatment levels of Ang III and LEP, the changes in their histopathological characteristics, and coefficient correlations were analyzed. The three groups exhibited a drastic decrease in serum Ang III and LEP levels compared to the baseline and control. The effects of Losartan, Telmisartan, and Candesartan on the end organs of the liver, kidney, and heart, did not show any alterations. There was a weak positive correlation between the two factors. In conclusion; Losartan, Telmisartan, and Candesartan significantly decreased the activity of the RAS via their effect on Ang III and LEP levels as another mechanism for their efficacy in treating cardiovascular illnesses.
- 31 December 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (4) , 2425-2438
Open AccessImpact of Angiotensin Receptor Blockers on Angiotensin III and Leptin in Rabbits
Angiotensin III (Ang III) properties include chemotaxis, creation development factors, and chemokines, which are also involved in renal and cardiovascular functions. Angiotensin receptor blockers (ARBs) are commonly used to treat cardiovascular illnesses. One factor that contributes to controlling blood pressure and resting metabolic rate is the protein Leptin (LEP). This study aimed to analyze ARB's (Losartan, Telmisartan, or Candesartan) effects on the levels of Ang III and LEP in rabbits. The characterization of the relationship between the two factors will be studied. The study was conducted on forty Oryctolagus cuniculus male rabbits. They were divided into four groups, randomly. Treated daily for ten days with intraperitoneal Losartan 0.7 mg/kg/day [G I], Telmisartan 0.6 mg/kg/day [G II], Candesartan 0.1 mg/kg/day [G III], and Control [G IV]. Pre- and post-treatment levels of Ang III and LEP, the changes in their histopathological characteristics, and coefficient correlations were analyzed. The three groups exhibited a drastic decrease in serum Ang III and LEP levels compared to the baseline and control. The effects of Losartan, Telmisartan, and Candesartan on the end organs of the liver, kidney, and heart, did not show any alterations. There was a weak positive correlation between the two factors. In conclusion; Losartan, Telmisartan, and Candesartan significantly decreased the activity of the RAS via their effect on Ang III and LEP levels as another mechanism for their efficacy in treating cardiovascular illnesses.
- Open Access
- 21 March 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (1) , 611-627
Impact of Isoniazid and Rifampicin on Chemokines with Clinical Parameters in Tuberculosis Patients
One of the most common and deadly diseases is tuberculosis, which has been known to be originated in ancient times. The assessment of the effectiveness of treatment regimens involves the monitoring of adverse events and the estimation of biomarkers. Serum biomarkers: Chemokine, Hematology, Liver function tests, and Kidney function tests were studied in forty tuberculosis patients of pulmonary and extra-pulmonary with its correlation. The monitoring and follow-up were assessed for the presence of any adverse effects, and compliance to treatment by Isoniazid 300 mg/kg, and Rifampicin 600 mg/kg during the study period. A significant difference was recorded between pulmonary and extra-pulmonary patients of the serum chemokine CXCL8 after one and two months of the treatment. The serum CXCL8 was increased in pulmonary and decreased in extra-pulmonary TB patients. The conclusion of this study described that chemokines play a role in mediating an effective immune-modulatory role during the treatment of TB infection and the therapeutic drug monitoring for compliance with TB treatment. A significant difference was noticed in the levels of liver enzymes (AST and ALT) between pulmonary and extra-pulmonary tuberculosis. Kidney function parameters showed a difference in creatinine levels between the two studied groups.
- 21 March 2023
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 16 (1) , 611-627
Open AccessImpact of Isoniazid and Rifampicin on Chemokines with Clinical Parameters in Tuberculosis Patients
One of the most common and deadly diseases is tuberculosis, which has been known to be originated in ancient times. The assessment of the effectiveness of treatment regimens involves the monitoring of adverse events and the estimation of biomarkers. Serum biomarkers: Chemokine, Hematology, Liver function tests, and Kidney function tests were studied in forty tuberculosis patients of pulmonary and extra-pulmonary with its correlation. The monitoring and follow-up were assessed for the presence of any adverse effects, and compliance to treatment by Isoniazid 300 mg/kg, and Rifampicin 600 mg/kg during the study period. A significant difference was recorded between pulmonary and extra-pulmonary patients of the serum chemokine CXCL8 after one and two months of the treatment. The serum CXCL8 was increased in pulmonary and decreased in extra-pulmonary TB patients. The conclusion of this study described that chemokines play a role in mediating an effective immune-modulatory role during the treatment of TB infection and the therapeutic drug monitoring for compliance with TB treatment. A significant difference was noticed in the levels of liver enzymes (AST and ALT) between pulmonary and extra-pulmonary tuberculosis. Kidney function parameters showed a difference in creatinine levels between the two studied groups.
- 1 September 2017
- Published by Journal of Baghdad College of Dentistry in Journal of Baghdad College of Dentistry
- Vol. 29 (3) , 45-53
Treatment of Recurrent Aphthous Ulceration by Mastic Orabase
- 1 September 2017
- Published by Journal of Baghdad College of Dentistry in Journal of Baghdad College of Dentistry
- Vol. 29 (3) , 45-53
Treatment of Recurrent Aphthous Ulceration by Mastic Orabase
- Open Access
- 1 January 2014
- Published by Science Publishing Group in American Journal of Clinical and Experimental Medicine
- Vol. 2 (6) , 137-150
Efficacy of Topical Zinc Sulphate on Wound Healing of Experimentally Induced Skin Ulcers by Nicorandil and Induction Effect on Transforming Growth Factor-β
Induced ulcer wound repair needs re-epithelialisation to replace necrotised and/or damaged tissue and to re-establish its integrity. Transforming growth factor-β (TGF-β) affects all cell types that are involved in all stages of wound healing. The assessment of induced ulcer wound healing activity was carried out through three models: First, excision model, second, induced ulcer wound using 50 mg Aspirin, and third by using 10 mg Nicorandil wound model. The animals were divided into eight groups; and were treated with different concentrations of Zinc sulphate, compared to their controls. The efficacy of Zinc sulphate on healing process of lesion induced was assessed by; body weight change, macroscopical appearance of the induced ulcers (ulcer area and wound contraction), microscopically appearance and histopathology; as well as qualitative assessment Moreover, the effect of ulcer induction on the serum levels of TGF-β according to the procedure of the kit was assessed in all groups. Different concentrations of topical Zinc sulphate have not significantly enhanced the healing of excision wounds. Thirty milligram Zinc sulphate has not significantly enhanced the healing of lesion ulcer induced by 50 mg Aspirin or 10 mg Nicorandil. Nevertheless, the 50 mg Aspirin and 10 mg Nicorandil caused delay in healing. In all groups, a significant reduction in ulcer area was observed compared to that of the baseline. Besides, a significant elevation in wound contraction was noticed compared to that of the baseline. Qualitative assessment of the healing process of the induced ulcer confirms that Aspirin or Nicorandil delay healing. Assessment of serum TGF-β level in serum showed no statistical significant elevation in those groups treated with different concentrations of Zinc sulphate compared to their control, while TGF-β level showed non-significant reduction in the group of induced ulcer by Aspirin or Nicorandil and treatment with 30 mg Zinc sulphate, compared to their controls. In conclusion, Nicorandil cause ulceration in the same manner of Aspirin, which delay the healing process, and TGF-β appears to play a more profound role in the healing process perforations than in the healing of induced ulcers in skin.
- 1 January 2014
- Published by Science Publishing Group in American Journal of Clinical and Experimental Medicine
- Vol. 2 (6) , 137-150
Open AccessEfficacy of Topical Zinc Sulphate on Wound Healing of Experimentally Induced Skin Ulcers by Nicorandil and Induction Effect on Transforming Growth Factor-β
Induced ulcer wound repair needs re-epithelialisation to replace necrotised and/or damaged tissue and to re-establish its integrity. Transforming growth factor-β (TGF-β) affects all cell types that are involved in all stages of wound healing. The assessment of induced ulcer wound healing activity was carried out through three models: First, excision model, second, induced ulcer wound using 50 mg Aspirin, and third by using 10 mg Nicorandil wound model. The animals were divided into eight groups; and were treated with different concentrations of Zinc sulphate, compared to their controls. The efficacy of Zinc sulphate on healing process of lesion induced was assessed by; body weight change, macroscopical appearance of the induced ulcers (ulcer area and wound contraction), microscopically appearance and histopathology; as well as qualitative assessment Moreover, the effect of ulcer induction on the serum levels of TGF-β according to the procedure of the kit was assessed in all groups. Different concentrations of topical Zinc sulphate have not significantly enhanced the healing of excision wounds. Thirty milligram Zinc sulphate has not significantly enhanced the healing of lesion ulcer induced by 50 mg Aspirin or 10 mg Nicorandil. Nevertheless, the 50 mg Aspirin and 10 mg Nicorandil caused delay in healing. In all groups, a significant reduction in ulcer area was observed compared to that of the baseline. Besides, a significant elevation in wound contraction was noticed compared to that of the baseline. Qualitative assessment of the healing process of the induced ulcer confirms that Aspirin or Nicorandil delay healing. Assessment of serum TGF-β level in serum showed no statistical significant elevation in those groups treated with different concentrations of Zinc sulphate compared to their control, while TGF-β level showed non-significant reduction in the group of induced ulcer by Aspirin or Nicorandil and treatment with 30 mg Zinc sulphate, compared to their controls. In conclusion, Nicorandil cause ulceration in the same manner of Aspirin, which delay the healing process, and TGF-β appears to play a more profound role in the healing process perforations than in the healing of induced ulcers in skin.
- Open Access
- 2 October 2012
- Published by Springer Nature in BMC Dermatology
- Vol. 12 (1) , 1-18
The treatment of melasma by silymarin cream
Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma patients.
- 2 October 2012
- Published by Springer Nature in BMC Dermatology
- Vol. 12 (1) , 1-18
Open AccessThe treatment of melasma by silymarin cream
Melasma is an acquired increased pigmentation of the skin characterized by symmetrical and confluent grey-brown patches usually on the areas of the face exposed to the sun. Silymarin strongly prevents photocarcinogenesis, and significantly prevented melanin production. The objectives of this study were the assessment of safety and efficacy of topical Silymain (SM) cream in a double-blind placebo controlled study for treatment of melasma patients.
- 1 February 2012
- Vol. 25 (1) , 39-43
Topical lavender oil for the treatment of recurrent aphthous ulceration.
To determine the laboratory and clinical efficacy of lavender oil in the treatment of recurrent aphthous ulceration (RAU). This was a randomized double-blind, placebo-controlled study performed firstly to treat the induced ulcers by different methods in experimental animals (rabbits) treated with lavender oil or placebo. Clinical and histological healing was established by measuring the area of the ulcer and inflammation levels in each test group. Secondly, safety/toxicity; the median lethal dose (LD50) was studied in albino mice, and dermal irritation test was performed by primary irritation to the skin and measured by a patch-test technique on the intact skin of the albino rabbit. Thirdly, antibacterial effect; lavender oil was screened against bacteria obtained from swab specimen of human subjects' RAU using disc diffusion method. Fourthly, clinical study; 115 subjects (mean age 38 years, mean weight 75 kg) were divided into two groups of subjects topically treated with lavender oil or placebo. The clinical efficacy was assessed by inflammation level, erythema, edema, ulcer duration, ulcer size, mean area under the curve of ulcer area, healing time, and associated pain intensity and reduction. Animals treated with lavender oil showed a significant ulcer size reduction, increased rate of mucosal repair, and healing within 3 days of treatment compared to baseline and placebo groups [2-3 days (90%), 4 days (10%)] (P=0.001). The intraperitoneal LD50 value in mice was 6.5 gm/kg; clinical dermal irritation test showed no sign of irritation in the tested products. Lavender oil showed a broad antibacterial activity against all tested strains; it exhibited significant inhibition on tested bacteria where the value of zone of inhibition ranged from 14.5-24 mm vs Streptomycin (25 microg/disc) 12-22 +/- 0.5 mm; MIC was > 6.4-36 mg/ml. RAU patients treated with lavender oil showed a significant reduction in inflammation level, ulcer size, healing time, from 2-4 days [2 days (40%), 3 days (50%), 4 days (10%)], and pain relief mostly from the first dose, compared to baseline and placebo. No side effects were reported.
- 1 February 2012
- Vol. 25 (1) , 39-43
Topical lavender oil for the treatment of recurrent aphthous ulceration.
To determine the laboratory and clinical efficacy of lavender oil in the treatment of recurrent aphthous ulceration (RAU). This was a randomized double-blind, placebo-controlled study performed firstly to treat the induced ulcers by different methods in experimental animals (rabbits) treated with lavender oil or placebo. Clinical and histological healing was established by measuring the area of the ulcer and inflammation levels in each test group. Secondly, safety/toxicity; the median lethal dose (LD50) was studied in albino mice, and dermal irritation test was performed by primary irritation to the skin and measured by a patch-test technique on the intact skin of the albino rabbit. Thirdly, antibacterial effect; lavender oil was screened against bacteria obtained from swab specimen of human subjects' RAU using disc diffusion method. Fourthly, clinical study; 115 subjects (mean age 38 years, mean weight 75 kg) were divided into two groups of subjects topically treated with lavender oil or placebo. The clinical efficacy was assessed by inflammation level, erythema, edema, ulcer duration, ulcer size, mean area under the curve of ulcer area, healing time, and associated pain intensity and reduction. Animals treated with lavender oil showed a significant ulcer size reduction, increased rate of mucosal repair, and healing within 3 days of treatment compared to baseline and placebo groups [2-3 days (90%), 4 days (10%)] (P=0.001). The intraperitoneal LD50 value in mice was 6.5 gm/kg; clinical dermal irritation test showed no sign of irritation in the tested products. Lavender oil showed a broad antibacterial activity against all tested strains; it exhibited significant inhibition on tested bacteria where the value of zone of inhibition ranged from 14.5-24 mm vs Streptomycin (25 microg/disc) 12-22 +/- 0.5 mm; MIC was > 6.4-36 mg/ml. RAU patients treated with lavender oil showed a significant reduction in inflammation level, ulcer size, healing time, from 2-4 days [2 days (40%), 3 days (50%), 4 days (10%)], and pain relief mostly from the first dose, compared to baseline and placebo. No side effects were reported.
- 1 January 2012
- Vol. 17 (1) , 34-8
Protective effect of silymarin during coronary artery bypass grafting surgery.
An inflammatory response and systemic oxidative stress are directly caused by coronary artery bypass grafting (CABG) surgery. Cytokines, such as interleukin (IL) 1β, IL-6 and tumour necrosis factor-α (TNF-α), can also be stimulated. Reducing the release of pro-inflammatory cytokines plays an important role in limiting the postoperative inflammatory response. Silymarin has strong anti-inflammatory, antioxidant and cytoprotective properties. To investigate the protective anti-inflammatory and antioxidant properties of silymarin against the inflammation and oxidative stresss inherent to CABG surgery. Of the 102 patients undergoing elective first-time CABG surgery that were recruited, 50 (49.02%) received silymarin treatment and 52 (50.9%) were controls. Plasma cytokine levels (IL-1β, IL-6 and TNF-α) were measured preoperatively, 6 h and 24 h after CABG surgery. C-reactive protein (CRP) levels, trolox equivalent antioxidant capacity (TEAC) and glutathione (GSH) and malondialdehyde (MDA) levels were analyzed. Postoperative cytokine levels in the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels. The area under the curve for cytokines and CRP for the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels. Postoperative levels of TEAC and MDA in the silymarin-treated group were significantly lower than in the control group. GSH levels were significantly elevated in the silymarin group compared with control. No side effects or mortality were associated with the use of silymarin. The anti-inflammatory and antioxidant effects of silymarin treatment provided protection against reperfusion injury and inflammation after CABG surgery.
- 1 January 2012
- Vol. 17 (1) , 34-8
Protective effect of silymarin during coronary artery bypass grafting surgery.
An inflammatory response and systemic oxidative stress are directly caused by coronary artery bypass grafting (CABG) surgery. Cytokines, such as interleukin (IL) 1β, IL-6 and tumour necrosis factor-α (TNF-α), can also be stimulated. Reducing the release of pro-inflammatory cytokines plays an important role in limiting the postoperative inflammatory response. Silymarin has strong anti-inflammatory, antioxidant and cytoprotective properties. To investigate the protective anti-inflammatory and antioxidant properties of silymarin against the inflammation and oxidative stresss inherent to CABG surgery. Of the 102 patients undergoing elective first-time CABG surgery that were recruited, 50 (49.02%) received silymarin treatment and 52 (50.9%) were controls. Plasma cytokine levels (IL-1β, IL-6 and TNF-α) were measured preoperatively, 6 h and 24 h after CABG surgery. C-reactive protein (CRP) levels, trolox equivalent antioxidant capacity (TEAC) and glutathione (GSH) and malondialdehyde (MDA) levels were analyzed. Postoperative cytokine levels in the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels. The area under the curve for cytokines and CRP for the silymarin group were significantly lower compared with preoperative levels, and were significantly lower compared with postoperative control group levels. Postoperative levels of TEAC and MDA in the silymarin-treated group were significantly lower than in the control group. GSH levels were significantly elevated in the silymarin group compared with control. No side effects or mortality were associated with the use of silymarin. The anti-inflammatory and antioxidant effects of silymarin treatment provided protection against reperfusion injury and inflammation after CABG surgery.